Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074321 · ClinicalTrials.gov registry record · Phase 1
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT00074321: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00074321 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00074321, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy, such as irinotecan, oxaliplatin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. This phase I trial is studying the side effects and best dose of irinotecan, oxaliplatin, and capecitabine in treating patients with unresectable solid tumors.
Interventions
- OTHER laboratory biomarker analysis
- DRUG oxaliplatin
- DRUG capecitabine
- OTHER pharmacological study
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2003-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00074321
The ClinicalTrials.gov registry entry for NCT00074321 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00074321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00074321 about?
NCT00074321 is a clinical study titled "Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors". Drugs used in chemotherapy, such as irinotecan, oxaliplatin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. This phase I trial is studying the side effects and best dose of i...
What is the current status of trial NCT00074321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2003-11.
What interventions are being tested in trial NCT00074321?
The interventions under investigation include: laboratory biomarker analysis (OTHER), oxaliplatin (DRUG), capecitabine (DRUG), pharmacological study (OTHER), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00074321?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.